Why Is Summit Therapeutics Inc. (SMMT) Stock Down -20% Today?
Key Takeaways
- SMMT shares fell approximately 20% in premarket trading on Friday, May 1, 2026, dropping from a prior close of approximately $20.83 to around $16.66.
- The primary catalyst was the HARMONi-3 interim PFS analysis miss, with the Phase III global trial failing to meet expectations for its squamous cohort, undermining the ivonescimab thesis.
- Q1 2026 financials also disappointed, with a GAAP EPS loss of -$0.29, significantly wider than the consensus estimate of -$0.077, and GAAP operating expenses surging to $195.2 million from $66.8 million a year earlier.
- Analyst price target cuts followed, including Piper Sandler lowering its target to $16 from $17, while other analysts flagged elevated risk around the FDA PDUFA date of November 14, 2026.
- The sell-off raises serious questions about the regulatory pathway for ivonescimab in the U.S. market and whether prior China-based trial results can be replicated globally.
- Traders are now focused on the FDA BLA decision expected November 14, 2026 and whether the HARMONi-3 non-squamous cohort data can restore investor confidence.
Opening Summary
Summit Therapeutics Inc. (SMMT) is a clinical-stage biopharmaceutical company headquartered in Miami, Florida, focused on the development and commercialization of ivonescimab — an investigational bispecific antibody targeting PD-1 and VEGF — primarily for non-small cell lung cancer (NSCLC). Shares plunged approximately 20% in premarket trading on May 1, 2026, falling from the prior close of roughly $20.83 to near $16.66. The sell-off was triggered by a disappointing interim progression-free survival (PFS) analysis from the HARMONi-3 Phase III squamous cohort, coinciding with a wider-than-expected Q1 2026 earnings loss. The combination of a clinical setback and a deteriorating financial picture drove aggressive pre-market selling.
HARMONi-3 Interim PFS Miss
The central driver of Friday's sharp decline was the failure of the HARMONi-3 squamous cohort interim PFS analysis to meet investor expectations. HARMONi-3 is a pivotal global Phase III study evaluating ivonescimab combined with chemotherapy versus pembrolizumab (Keytruda) combined with chemotherapy in first-line NSCLC — a highly competitive and commercially significant indication. The interim analysis, which had been anticipated in Q2 2026 and was seen as a key de-risking catalyst for the stock, did not replicate the strong signals previously observed in China-based HARMONi-2 and HARMONi-6 studies. This marks a recurring concern for Summit: earlier in September 2025, longer-term follow-up data from a separate global ivonescimab trial showed results that failed to validate China-derived signals, including a potential overall survival concern in North American and European patients. The HARMONi-3 interim miss compounds that narrative and throws the global applicability of ivonescimab's efficacy profile back into doubt.
Q1 2026 Earnings Widen the Blow
The clinical setback arrived alongside a Q1 2026 financial report that offered little offsetting comfort. Summit posted a GAAP net loss of $189.4 million, or -$0.24 per share, compared to a $62.9 million loss in Q1 2025. On a non-GAAP basis, the loss was $116.6 million, or -$0.15 per share — slightly better than the FactSet estimate of -$0.17, though the GAAP figure trailed expectations significantly. GAAP operating expenses ballooned to $195.2 million from $66.8 million a year ago, largely driven by a $61.7 million increase in stock-based compensation tied to modifications of performance-based stock options. With no commercial revenue yet, the company's financial runway and burn rate are subject to heightened scrutiny as clinical milestones slip.
Analyst Downgrades and Target Cuts
The dual-catalyst selloff immediately prompted analyst reactions. Piper Sandler lowered its price target on SMMT to $16 from $17, reflecting reduced confidence in the near-term pipeline. One analyst reiterated a Buy/High Risk rating while maintaining a $40 price target, acknowledging the HARMONi-3 interim miss but arguing there remains meaningful upside if the FDA PDUFA decision on November 14, 2026 goes favorably. The divergence in analyst views reflects genuine uncertainty: some see the HARMONi-3 miss as a manageable setback given the existing BLA filing, while others view it as a fundamental challenge to the drug's commercial credibility in Western markets.
Market Context and Trading Activity
Trading volume in SMMT premarket was substantially elevated relative to its 30-day average premarket activity, reflecting institutional and retail re-positioning in response to the clinical data. The broader biotech sector has faced persistent headwinds in 2026 amid macro uncertainty and elevated interest rates, providing little cushion for single-stock clinical disappointments. SMMT had already lost significant ground from its all-time high of approximately $36.91 reached in April 2025, and was trading down roughly 11.8% over the trailing 12 months even before Friday's move. The stock had recently shown some recovery, gaining 6.53% on April 30 ahead of the earnings print, making the reversal even more pronounced. Technically, a drop to the $16 range would push SMMT toward key longer-term support near its 52-week lows.
Trending AI Robots
For traders navigating high-volatility biotech events like SMMT's premarket plunge, Tickeron's Trending AI Robots page provides a curated selection of the platform's strongest-performing AI trading bots under current market conditions. Tickeron operates hundreds of automated bots covering thousands of tickers, each varying by strategy, timeframe, risk profile, and performance metrics — from momentum and breakout approaches to mean-reversion and sector-specific tactics. Rather than sifting through the entire bot library, the Trending AI Robots section highlights only those demonstrating the most consistent and relevant performance given prevailing market dynamics. Traders looking to complement their own research with systematic, data-driven tools may find this resource a valuable addition to their workflow.
What Comes Next for SMMT
The most consequential upcoming event for SMMT remains the FDA PDUFA decision date of November 14, 2026 on ivonescimab's Biologics License Application (BLA) for second-line NSCLC in combination with chemotherapy, based on the original global HARMONi trial data. This application was accepted by the FDA in early 2026 and targets approximately 14,000 eligible U.S. patients annually. The next major clinical data point will be the HARMONi-3 non-squamous cohort, with final PFS analysis expected in H1 2027. Investors will also monitor whether Summit revises its clinical strategy in response to the squamous interim miss and whether the FDA review process surfaces any additional data requests. The company's next scheduled earnings date is May 7, 2026, which will give management an opportunity to address investor concerns directly. Key risks include continued divergence between China-based trial results and global outcomes, increasing cash burn, and competition from established checkpoint inhibitor combinations in the NSCLC market.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Financial writer and active order flow futures trader with a focus on fundamental analysis, macroeconomic factors, and equity research. I make in-depth blogs on stocks and ETFs, bridging the gap between raw market data and real-world trading decisions.
SMMT's Stochastic Oscillator stays in oversold zone for 4 days
The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an uptrend is expected.
Technical Analysis (Indicators)
Bullish Trend Analysis
Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where SMMT advanced for three days, in of 280 cases, the price rose further within the following month. The odds of a continued upward trend are .
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on August 17, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on SMMT as a result. In of 104 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are .
The Moving Average Convergence Divergence Histogram (MACD) for SMMT turned negative on August 18, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 48 similar instances when the indicator turned negative. In of the 48 cases the stock turned lower in the days that followed. This puts the odds of success at .
SMMT moved below its 50-day moving average on August 13, 2026 date and that indicates a change from an upward trend to a downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where SMMT declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .
The Aroon Indicator for SMMT entered a downward trend on August 06, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating slightly worse than average price growth. SMMT’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. SMMT’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 92, placing this stock better than average.
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (16.667) is normal, around the industry mean (20.145). P/E Ratio (26.355) is within average values for comparable stocks, (22.992). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (3.861). Dividend Yield (0.000) settles around the average of (0.018) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (444.692).
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a developer of novel medicines
Industry Biotechnology
Advertisement